In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided by chance. Participants will receive 1 formulation for 10 days (first treatment period) and the other formulation for 5 days (second treatment period). The study will last up to 96 days. Only men can participate in this clinical study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
152
Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Altasciences
Cypress, California, United States
Altasciences Clinical Los Angeles, Inc.
Los Angeles, California, United States
AUC0-24h,NNC0385-0434,day10; area under the plasma concentrationtime curve during a dosing interval
Measured in h \* nmol/L
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
Cmax,NNC0385-0434,day10; maximum observed plasma concentration of NNC0385-0434
Measured in nmol/L
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
tmax,NNC0385-0434,day10; time from dose administration to maximum observed plasma concentration of NNC0385- 0434
Measured in hours
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.